BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation StudyAmber Louw, Oluf Dimitri Røe, Siaw Ming Chai et al.|Journal of Thoracic Oncology|2022Cited by 65
BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapyVasiliki Panou, Oluf Dimitri Røe, Amber Louw et al.|Unknown|2020Cited by 1